[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ResoTher Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100551839",false,"NCT06465303","A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)","An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)","Inclusion Criteria:\n\n* Informed consent for participation in the study has been obtained prior to initiating any study-specific procedures\n* Men between 18-85 years of age and post-menopausal women up to 85 years of age\n* Acute onset of chest pain of \\\u003C 12 hours duration\n* STEMI as characterized on ECG by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with a minimum of 1 mm concordant ST elevation or 1 mV ST elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior acute myocardial infarction (AMI)\n* Eligible for primary PCI\n* NLR in the range of 7-17 at hospital admission. In patients with chest pain lasting \\> 3 - ≤ 6 hours at admission, the NLR should be in the range of 4.8-17 and for patients with chest pain lasting ≤ 3 hours at admission, the NLR should be in the range of 4.8-17, or the neutrophile count should be ≥ 9 x 10E9\u002FL, irrespective of the lymphocyte count. For STEMI patients with an anterior or anterolateral infarction, the NLR should be ≥3.\n\nExclusion Criteria:\n\n* Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry\n* Previous exposure to RTP-026\n* Time from symptoms onset to primary PCI \\> 12 hours\n* Previous CABG\n* Evidence of active malignant disease\n* Ongoing treatment with immune suppressive compounds\n* Any condition that, in the view of the investigator, would suggest that the patient is unable to comply with the study protocol and procedures\n* Known contraindications to CMR\n* ORBI Risk Score \\> 12","ALL","18 Years","85 Years",{"count":19,"type":20},96,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026.\n\nThe study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).",[26],"ST Elevation Myocardial Infarction","RECRUITING","2025-09-16",{"date":30,"type":31},"2025-09-22","ACTUAL",{"date":33,"type":31},"2024-07-16",{"date":35,"type":20},"2025-12-21",{"name":37,"class":38},"ResoTher Pharma","INDUSTRY",""]